Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug GMP Report > Cispharma Gets Form 483 Over Testing, Drug Quality Concerns

Drug GMP Report

October 2012

Cispharma Gets Form 483 Over Testing, Drug Quality Concerns

Cispharma has received a Form 483 with several manufacturing observations, including a lack of evidence that a distributed portion of a lot was acceptable.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Ranbaxy Compliance Reforms Reflect FDA Manufacturing Recommendations Novartis 483 Highlights Rocky Remediation at Nebraska Plant Concerns with Contract Manufacturer Draw Complete Response for Allergan’s Levadex FDA Warning Letter(s)

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.